IXP Lifesciences Catalyst Fund Launches with Rs 200 Crore Corpus to Back Early-Stage Innovations
IXP, a Life Sciences-focused venture capital firm backed by JV Ventures, has launched its first fund to support early-stage companies. The IXP Lifesciences Catalyst Fund is set to deploy Rs 200 crore, with an additional Rs 100 crore greenshoe option, to build a robust portfolio of 20-25 B2B companies spanning pre-seed to Series A stages.
The fund is strategically designed to bridge critical gaps in life sciences, investing in pharmaceuticals, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals. Unlike conventional VC models, IXP takes a hands-on approach, actively engaging in the development process from ideation to scaling.
A Unique Venture Studio Model
Through IXP Venture Studio, the firm will co-create startups alongside scientists, focusing on transformative solutions addressing unmet market needs. A key initiative, the Venturepreneur Program, is designed to empower scientists as founders, guiding them through the entrepreneurial journey.
Recognizing the capital-intensive nature of life sciences, IXP offers portfolio companies access to critical infrastructure such as laboratories, R&D resources, and industry networks. These services are facilitated by PoweRx, the Life Sciences vertical of JV Ventures, creating a strong support system for innovation.
Building a Thriving Life Sciences Ecosystem
IXP (Innovation Acceleration Platform) is built on the foundation of a deeply experienced team that understands the long gestation periods of life sciences R&D. By integrating startups into a collaborative ecosystem, the fund aims to fast-track scientific breakthroughs and drive market-ready solutions.
With this initiative, IXP is poised to shape the future of life sciences entrepreneurship, fostering innovations that have the potential to transform healthcare, sustainability, and biotechnology.
